Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% in ...

Novo Nordisk (NVO) said it has become aware of several hundred units of Ozempic injection outside the Novo Nordisk authorized supply chain in the U.S. The US Food and Drug Administration has also ...

Weight loss leader Novo Nordisk has had a poor performance at the ... So first of all, it's important to call out we have no new data. And therefore, our confidence remains to be the same.

Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for ...

Therefore, I think buying Novo Nordisk stock at these prices will prove wise in hindsight. Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and ...

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...

Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing ... that have the ability to conduct monetary policy with no political tampering have better outcomes for their economies.

Novo Nordisk (NVO) stock plunges 44% YoY, hitting a 52-week low as bearish signals pile up. New obesity drug deal fails to excite investors, with Eli Lilly’s rival treatment set to launch first.

The move gives Novo Nordisk and Eli Lilly a bit more time of having the only patent-protected GLP-1 drugs on the market. Viking Therapeutics moves toward the head of the pack to become No. 3 ...